Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of March 2025, specifically detailing a share repurchase executed on March 25, 2025. The company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, cash flow). Key metrics for the reported transaction are as follows:
- Date of Purchase: March 25, 2025
- Shares Purchased: 835,000 ordinary shares
- Price Range: Lowest 1,485.50p; Highest 1,512.50p
- Volume-Weighted Average Price (VWAP): 1,498.58p
- Trading Venue: London Stock Exchange (XLON)
- Broker: Citigroup Global Markets Limited
Following this purchase, GSK holds 183,942,390 ordinary shares in treasury. The total number of ordinary shares in issue (excluding treasury shares) is 4,131,272,456. The total number of voting rights is 4,131,272,456.
Material Changes and Program Status
This transaction is part of GSK's existing buyback programme, executed pursuant to a non-discretionary agreement entered into with the broker on February 24, 2025. Since the inception of this agreement on February 24, 2025, the company has purchased a total of 14,872,087 ordinary shares. The filing does not report material changes to revenue, profit, or debt levels, as it is a disclosure of a capital transaction.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced as being described on pages 277 to 285 of the GSK 2024 Annual Report on Form 20-F. No new guidance or management commentary regarding operational outlook is provided in this specific filing.
Investor Verification Checklist
- Verify the total number of treasury shares held (183,942,390) against the company's latest capital structure disclosures.
- Confirm the remaining authorization under the buyback programme initiated on February 24, 2025.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for detailed risk factors referenced in the cautionary statement.
- Monitor subsequent filings for updates on the total volume of shares repurchased under the current programme.